Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study

Table 3 Risk of recurrent herpes zoster on rheumatoid arthritis patients with history of herpes zoster during first bDMARD or tsDMARD use

	Events	Person-years	Incidence	Previous zoster to index date^a	Time-to-event^b	aHR (95% CI)	P value	aHR (95% CI)	P value
Etanercept (n=311)	71 (22.8)	1004	70.7	1.9 (0.8–3.3)	1.7 (0.8–3.3)	Reference		1.22 (0.75–2.00)	0.421
Infliximab (n=186)	35 (18.8)	435	80.5	2.2 (1.1–3.8)	1.8 (0.4–3.1)	0.88 (0.55–1.41)	0.599	1.08 (0.62–1.87)	0.784
Adalimumab (n=412)	96 (23.3)	1018	94.3	2.2 (0.9–3.9)	1.2 (0.5–2.6)	1.22 (0.85–1.75)	0.276	1.50 (0.93–2.40)	0.094
Golimumab (n=190)	26 (13.7)	310	83.9	3.2 (1.5–4.7)	0.9 (0.5–1.6)	0.54 (0.27–1.09)	0.084	0.66 (0.32–1.37)	0.268
Tocilizumab (n=247)	34 (13.8)	392	86.7	3.0 (1.5–4.8)	0.9 (0.3–1.8)	0.95 (0.57–1.58)	0.838	1.16 (0.67–2.00)	0.590
Tofacitinib (n=143)	18 (12.6)	97	185.6	3.9 (2.0–6.2)	0.3 (0.1–0.8)	3.01 (1.49–6.11)	0.002	3.69 (1.77–7.69)	<0.001
Abatacept (n=228)	33 (14.5)	394	83.8	2.9 (1.4–4.6)	1.1 (0.5–2.3)	0.82 (0.50–1.34)	0.421	Reference

Adjusted hazard ratios calculated by multivariate Cox proportional hazards regression after adjustments for age, sex, number of csDMARD, Charlson comorbidity index, enrollment year, steroids use, and the period between the date of previous zoster and the index date
Incidence calculated as the number of events per 1000 person-years
^aPeriod between the date of previous herpes zoster to the index date, median (interquartile range)
^bYears to herpes zoster among participants with event, median (interquartile range)
bDMARD biological disease-modifying anti-rheumatic drugs, tsDMARD targeted synthetic disease-modifying anti-rheumatic drugs, aHR adjusted hazard ratio, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drugs

ISSN: 1478-6362